

CURRICULUM VITAE{PRIVATE }

COENRAAD F.M. HENDRIKSEN
Netherlands Vaccine Institute (NVI)
P.O.Box 457, 3720 AL BILTHOVEN
The Netherlands
Tel: +3130-2742503/2335
Fax: +3130-2744408

e-mail: Coenraad.Hendriksen@nvi-vaccin.nl

and

Department Animals in Science and Society (DWM)
Faculty Veterinary Medicine, Utrecht University
Yalelaan 2
3508 TD Utrecht
The Netherlands
Tel. + 31 30 2532511
Fax. + 31 30 2539227
e-mail: C.F.M.Hendriksen1@uu.nl

PERSONAL DATA

Name : Hendriksen, Coenradus Franciscus Maria
Nationality : Dutch
Date of birth : 6 October 1950
Place of birth : Huissen (NL)
Marital status : Married, two children
Home address : Galgenveldsdijk 3, 7271 PG Borculo (NL), tel. + 31 (0)545 271265

EDUCATION

Veterinary Sciences at the Utrecht University, The Netherlands:

M.Vet.Sc : October 1973

DVM : May 1975

PhD : Faculty of Veterinary Medicine, Utrecht University, November 1989.

Postdoc. training : Laboratory Animal Sciences at Utrecht University,
November 1991.

EXPERIENCE/EMPLOYMENT

1975-1979	Laboratory animal pathologist at TNO Toxicology and Nutrition, Zeist, The Netherlands
1979-1984 (full-time) 1984-1987 (part-time)	Teacher Anatomy/Pathology
1984-1987 (part-time) 1987-1989 (full-time)	Reserch Scientist at the Laboratory for the Control of Biological Products, RIVM, Bilthoven, The Netherlands
1989-	Animal Welfare Officer at the RIVM (Central Animal Laboratories) and senior scientist at the Laboratory for the Quality Control of Biologicals of the RIVM. From 2002 on at he Netherlands Vaccine Institute
1991- 2002	Coördinator of the RIVM Institute Center for Alternatives to Animal Testing
2000 (Part-time)-2009	Head of the Netherlands Centre for Alternatives to Animal Use
2000 (Part-time) -	Chair on Alternatives to Animal Use at the Faculty of Veterinary Medicine, Utrecht University

SIDE ACTIVITIES

1980-1989	Adviser of the Dutch Society for the Protection of Animals
1982-1990	Member supervisory board Foundation Laboratory Animals and Science.
1994-1998.	Member supervisory board Netherlands Centre for Alternatives to Animal testing (NCA)
1992-1999	Board member of the Dutch Association for Laboratory Animal Science
1993-2002	National representative Scientific Advisory Committee of the European Centre for the Validation of Alternative Methods (ECVAM), Ispra, (I)
1995-1996	Member Dutch Commission on Biotechnology
1996-	Member Editoreal Board of ALTEX (Alternativen zu Tierexperimenten)
1997-2002	Chairman of the Animal Ethics Commission of the Faculty of Biology, Farmacy and Chemistry of Utrecht University
2000-	Member Editorial Board of ATLA (Alternatives To Laboratory Animals)
2002-2008	Council Member Institute Laboratory Animal Research (ILAR) of the National Academy of Sciences (US)
2003-	Member Central Commission Animal Experiments (CCD), from 2008 on chairman of the committee. CCD is the advisory board

	to the Minister of Public Health concerning issues related to animal experimentation.
2003-	Chairman Steering Group Biologicals ECVAM
2003-2006	Board Member European Consensus Platform on Alternatives (ECOPA)
2004-	Member Supervisory board Biomedical Primate Research Centre (BPRC)
2004-2008	Member External Science Advisory Panel CEFIC-LRI
2004-2010	Member 'Beroepenveld' Committee Hogeschool Utrecht-Institute for Life Sciences & Chemistry
2004-	Member Mirror Group European Partnership on Alternative Approaches to Animal Testing (EPAA) of the European Commission
2005-	Member Scientific Board Doerenkamp-Zbinden Foundation, From 2009 on Chairman
2009-	Board Member of the Doerenkamp-Zbinden Foundation
2006-	Board member Alternatives Congress Trust
2006-	Chairman Prijs Alternatieven voor dierproeven
2007-	Chairman Dieter-Lutticke award
2007-	Member Committee Laboratory Animals & Biotechnology of the Royal Netherlands Academy of Arts and Sciences, The Netherlands
2008-	AAALAC <i>ad hoc</i> reviewer

HONORS

Fondation Internationale pour la Substitution de l'Experimentation Animale (FISEA), Luxemburg, December 1989

Russell and Burch Award. Humane Society of the US. Washington (USA), November 1993

Dorothy Hegarty Award. Fund for the Replacement of Animals in Medical Experiments (FRAME), March 1996.

Doerenkamp-Zbinden Award, Doerenkamp-Zbinden Foundation, Germany/Switzerland, August 2002

Felix Wankel Award, Felix Wankel Foundation, Germany, November 2002.

PUBLICATIONS

A. THESIS:

Alternatives to Animal Testing in Diphtheria and Tetanus Research. Replacement, Reduction and Refinement in Vaccine Potency Control and Serology. Utrecht University. November 1989.

B: BOOKS AND VOLUME ISSUES:

Hendriksen CFM. Laboratory Animals in Vaccine Production and Control. Kluwer Academic Publishers. Dordrecht, The Netherlands, 1988

Hendriksen CFM, Koëter HBWM. eds. Animals in Biomedical Research; Replacement, Reduction, Refinement, Present Opportunities and Future Prospects. Elsevier. Amsterdam, The Netherlands, 1991

De Geus B & Hendriksen CFM eds.. *In vivo* and *In vitro* production of monoclonal antibodies: current possibilities and future perspectives. 74th Forum in Immunology. In: Research in Immunology, No.6, Vol. 149: 529-620 (1998)

C: PROCEEDINGS:

Arthur A.J.van Iersel and Coenraad F.M.Hendriksen (Eds). Alternatives to Animal Testing in the Production and Quality Control of Vaccines: Present Practice and Prospectives. RIVM 1993.

Brown F, Cussler K and Hendriksen C. (eds). Replacement, Reduction and Refinement of Animal Experiments in the Development and Control of Biological Products. Dev.Biol.Stand. Vol.86, Karger, Basel (1996)

Hendriksen C and Morton D. (1999). Humane Endpoints in Animal Experiments for Biomedical Research. The Royal Society Medicine Press, London (UK). ISBN 1-85315-429-6.

Brown F, Hendriksen C and Sesardic D. (eds). Alternatives to Animals in the Development and Control of Biological Products for Human and Veterinary Use. Dev.Biol.Stand. Vol.101, Karger, Basel (1999)

Brown F, Hendriksen C and Sesardic D. and Cussler K (eds). Advancing Science and Elimination of the Use of Laboratory Animals for Development and Control of Vaccines and Hormones. Developments in Biologicals, Vol.111, Karger, Basel (2002)

D: REPORTS

Hendriksen CFM. Contra-advice LD-50 test. Presented to the Dutch Ministry of Public Health. March 1984.

Hendriksen CFM. Meer dan Routine Alleen. Mogelijkheden tot Vervanging, Vermindering en/of Verfijning van het Proefdiergebruik bij de productie en controle van vaccins. (More than routine only. Opportunities for replacement, reduction and refinement in the production and quality control of vaccines). Veterinary Public Health Inspectorate, Rijswijk, The Netherlands, January 1987.

Slob W, Hendriksen CFM. The statistical analysis of dilution series by maximum likelihood: an application to **in vitro** bioassays estimating the potency of the diphtheria component in vaccines by serology. RIVM report no. 958900001, 1989.

Hendriksen CFM, Gielen H, Kinderen R van, Liefde A de, Rooy H de, Visser J en With P de. Huisvesting proefdieren RIVM: Aanbevelingen. (Housing of Laboratory Animals at the RIVM; Recommendations). Internal RIVM report, 1990.

Hendriksen CFM, Gun JW van der, Marsman FR, Donk van de JM, Kreeftenberg JG. Assay for Potency of Vaccines Containing D and/or T Adsorbed Toxoid Using the Toxin Binding Inhibition Test as a Secondary Method for Measuring the Antitoxin Response to Vaccination. Report prepared for the World Health Organization (WHO), Geneva, Switzerland. 1991.

Loggen HG, Akkermans AM, Donk HJM van de, Kreeftenberg JG, Hendriksen CFM and Jong WH de. Onderzoek naar de mogelijkheden om **in vitro** antistof productie door immune cellen te gebruiken voor de controle van difterie en tetanus bevattende vaccins. (Study to the opportunities **in vitro** antibody production by immune cells for the quality control of diphtheria and tetanus toxoid vaccines). RIVM 1992, Report no. 458802001

Arnoud A.Akkermans, Coenraad F.M.Hendriksen, Frits R.Marsman, Wim H.de Jong, Huib J.M.v.d.Donk. Evaluation of a single dilution potency assay based upon serology of vaccines containing diphtheria toxoid: analysis for consistency in production and testing at the laboratory of the Control of Biological Products of the RIVM. RIVM 1993, Rapport nr. 172203001

Frits R.Marsman, Arnoud A.Akkermans, Coenraad F.M.Hendriksen, Wim H.de Jong. Evaluation of a single dilution potency assay based upon serology of vaccines containing diphtheria toxoid: statistical analysis. RIVM 1993, Rapport nr. 172203002

C.F.M.Hendriksen, J.Woltjes, J.W.van der Gun, A.M.Akkermans, J.W.Marsman, M.H.Verschure, K.Veldman. Interlaboratory validation of in vitro serological assay systems for potency testing of tetanus toxoid vaccines for veterinary use. RIVM 1993, Report no. 949106001

I.van Straaten-van de Kappelle, JW van der Gun, FR Marsman, CFM Hendriksen & HJM van de Donk. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine. RIVM 1995. Report no. 100003001

A.A.J.v.d.Ark, I. van Straaten-van de Kapelle, H.J.M.van de Donk en C.F.M.Hendriksen. Evaluation of Whole Cell Vaccine-induced humoral antibody responses in the Pertussis Serological Potency Test in relation to the Mouse Protection Test. RIVM 1997. Report no. 623860 004 (July 1997).

A.M.Akkermans en C.F.M.Hendriksen. Evaluatie en validatie van de single dilution assay in het RIVM difterie en tetanus werkzaamheidsonderzoek. RIVM 1998. Rapport nr. 623860005 (December 1998)

Björn Steen, Coenraad F.M.Hendriksen, John Visser, Klaus Cussler, David Morton and Femke Streijger. The evaluation of humane endpoints in pertussis vaccine potency testing. RIVM 1999. Report no. 623860007 (February 1999).

P.P.A.M.Lenaars en C.F.M.Hendriksen. Ontwikkeling van "COMParative Adjuvant Selection System". RIVM 1999. Rapport no. 62386006 (Juni 1999).

A.A.J.v.d.Ark, I. van Straaten-van de Kapelle, R.M.Olander, K.Enssle, S.S.Jadhav, H.J.M.van de Donk, C.F.M.Hendriksen. The Pertussis Serological Potency Test collaborative study to evaluate the replacement of the Mouse Protection Test. RIVM 1999. Report no. 623860008 (June 1999).

Coenraad Hendriksen en Rixt Komduur. Wetenschappelijke trendanalyse dierproeven. Rapport in opdracht van Min.VWS (2010)

D: ARTICLES

About 90 articles in peer reviewed journals

Feron VJ, Hendriksen CFM, Speek AJ, Til HP and Spit BJ. Lifespan oral toxicity study of vinyl chloride in rats. *Fd. Cosmet. Toxicol.* 1981; 19: 317-333.

Spit BJ, Feron VJ, Hendriksen CF.(1981). Ultrastructure of hepatic angiosarcoma in rats induced by vinyl chloride. *Exp Mol Pathol.* 35(2):277-84

Hendriksen CFM. Van dierproef tot alternatief (From animal test to alternative). *Leven en Laten Leven*, May-June 1983: 7-9.

Hendriksen CFM. Het Johns Hopkins Center for Alternatives to Animal Testing and the meeting "Acute Toxicity Testing: Alternative Approaches" organised by this center. *Tijdschr. Diergeneeskd* 1983; 108, 17: 683-684.

Hendriksen CFM. Dierproeven en proefdierbeperking (Animal testing and animal reduction). *Tijdschr. Diergeneeskd.* 1984; 109, 19: 754-762.

Hendriksen CFM. Dierproeven: mag het ook wat minder zijn? (Animal testing, can it be reduced). *Intermediair* 1984; 20: 41.

Hendriksen CFM. Onderzoek naar alternatieven voor dierproeven (Research to alternatives in animal testing). *Biotechniek* 1985; 24, 4: 51-52

Kreeftenberg JG, Gun J van der, Marsman FR, Asten JAAM van, Sekhuis VM and Hendriksen CFM. An investigation of a mouse model to estimate the potency of the diphtheria component in vaccines. *J. Biol. Stand.* 1985; 13: 229-234.

Hendriksen CFM. Laboratory animals in bacterial vaccine control and some opportunities for replacement, reduction and refinement. *ATLA* 1988; 16: 125-136.

Hendriksen CFM. Replacement, reduction and refinement in vaccine production and control. *Z. Versuchstierkd.* 1986; 28: 217.

Hendriksen CFM. Proefdierreductie in de vaccincontrole (Laboratory animal reduction in vaccine quality control). 213e Scientific Meeting, Bilthoven, January 29 1987.

Hendriksen CFM, Gun JW van der, Marsman FR and Kreeftenberg JG. The effects of reductions in the numbers of animals used for the potency assay of the diphtheria and tetanus components of adsorbed vaccines by the methods of the European Pharmacopoeia. *J. Biol. Stand.* 1987; 15: 353-362.

Hendriksen CFM, Gun JW van der, Kreeftenberg JG. De toxine binding inhibitie (ToBI-) test; een gevoelige en betrouwbare in vitro methode voor de bepaling van tetanus- en difterie antistoffen in sera (The toxin binding inhibition (ToBI-) test: a sensitive and reproducible in vitro method for the estimation of tetanus and diphtheria antibodies in human serum samples. *Berichten uit het RIVM (Annual Report RIVM)* 1988: 270-272.

Hendriksen CFM en Ruitenbergh EJ. AIDS en het dierexperimenteel onderzoek (AIDS and laboratory animal testing). *Almanak* 1988, Faculteit der Diergeneeskunde.

Hendriksen CFM, Gun JW van der, Nagel J and Kreeftenberg JG. The toxin binding inhibition test as a reliable in vitro alternative to the toxin neutralization test in mice for the estimation of tetanus antitoxin in human sera. *J. Biol. Stand.* 1988; 16, 4: 287-297.

Hendriksen CFM, Gun JW van der, Kreeftenberg JG. Combined estimation of tetanus and diphtheria antitoxin in human sera by the in vitro toxin binding inhibition (ToBI) test. *J. Biol. Stand.* 1989; 17, 2: 191-200.

Hendriksen CFM. Laboratory animals in bacterial vaccine control and some opportunities for replacement, reduction and refinement. *ATLA* 1988; 16: 125-136.

Hendriksen CFM. Proefdiergebruik in het vaccinonderzoek (The use of laboratory animals in vaccinology). In: *Proefdieren. Cahiers Bio-wetenschappen en Maatschappij* 1989; 14, 1: 18-25.

Hendriksen CFM, Gun JW van der, Kreeftenberg JG. The use of the toxin binding inhibition (ToBI) test for the estimation of the potency of the diphtheria component of vaccines. *J. Biol. Stand.* 1989; 17: 241-247.

Hendriksen CFM, Gun JW van der, Westendorp JHL, Slob W, Bieman M den, Hesp A, Zutphen LFM van. Potency testing of batches diphtheria and tetanus vaccine by using isogenic animals. *GV-SOLAS symposium proceedings, sept 1989, Hannover, BRD*, pp. 86

Hendriksen CFM. Vervanging, vermindering en verfijning binnen de productie en controle van vaccins (Replacement, reduction and refinement in the production and quality control of vaccines). *Biotechniek* 1989; 28, 3: 35-37.

Hendriksen CFM. De ontwikkeling der vaccinologie met bijzondere aandacht voor de veterinaire vaccins (The development in vaccinology with special emphasis to the veterinary vaccines). *ARGOS* 1990; 2: 30-34

Hendriksen CFM, Iersel A van. Animal experimentation and the search for alternatives at the RIVM. *Annual Scientific Report RIVM* 1990; 123-124.

Nab J, Hendriksen CFM. Alternatieven voor dierproeven (Alternatives to animal testing). In: Zutphen LFM van, Baumans V en Beijnen AC (eds). *Proefdieren en Dierproeven. Wetenschappelijke Uitgeverij Bunge, Utrecht*, 1991. pp. 298-313.

Hendriksen CFM. Alternatieven voor dierproeven (alternatives to animal testing). *Ned Tijdschr Geneesk* 1991; 135, 41: 1896-1900.

Hendriksen CFM. Some considerations on the use of animals in vaccine production and quality control. *Perspectives on Animal Research* 1991.

Hendriksen CFM, Iersel A van. Animal experimentation and the search for alternatives at the RIVM. *Alternativen zu Tierexperimenten (ALTEX)* 1991; 15: 86-87.

Hendriksen CFM, Gun JW van der, Marsman FR and Kreeftenberg JG. The use of the in vitro toxin binding inhibition (ToBI) test for the estimation of the potency of tetanus toxoid. *Biologicals* 1991; 19: 23-29.

Hendriksen CFM. Animal experimentation and the concept of alternatives. In: *Animals in Biomedical Research. Replacement, Reduction, Refinement, Present Opportunities and Future Prospects.* Hendriksen CFM, Koëter HBWM eds. Elsevier. Amsterdam, The Netherlands 1991, pp 1-17.

Hendriksen CFM. The use of animals in the production and quality control of biologicals: current practice and possible alternatives. In: *Animals in Biomedical Research. Replacement, Reduction, Refinement, Present Opportunities and Future Prospects.* Hendriksen CFM, Koëter HBWM eds. Elsevier. Amsterdam, The Netherlands 1991, pp 49-69.

Hendriksen CFM. The effect of alternatives on the use of animals in biomedical research. In: *Animals in Biomedical Research. Replacement, Reduction, Refinement, Present Opportunities and Future Prospects.* Hendriksen CFM, Koëter HBWM eds. Elsevier. Amsterdam, The Netherlands 1991, pp 273-285.

Koëter HBWM, Hendriksen CFM. Perspectives. In: Animals in Biomedical Research. Replacement, Reduction, Refinement, Present Opportunities and Future Prospects. Hendriksen CFM, Koëter HBWM eds. Elsevier. Amsterdam, The Netherlands 1991, pp 285-288.

Eric J. de Waal, Henk-Jan Schuurman, Coenraad Hendriksen, J.Gerard Loeber, Aalt van Dijk and Henk van Loveren. (1992) Effects of subcutaneous versus intravenous administration of cyclosporin A on rat thymic histology and pharmacokinetics. *Int.J.Immunopharmac.* 14, 6: 1101-1105.

Eric Claassen, Wim de Leeuw, Paul de Greeve, Coenraad Hendriksen and Wim Boersma. Freund's Complete Adjuvant: an effective but disagreeable formula. 44th Forum in Immunology, *Research in Immunology*; 5, 143: 478-483.

Coenraad Hendriksen, Marian Koedam, Coen Moolenbeek, Eric Claassen. Immunological and pathological study of rabbits given adjuvant: an evaluation of several regimens. 44th Forum in Immunology, *Research in Immunology*; 5, 143: 572-573.

Hendriksen CFM. Immunisation procedures en ongerief bij proefdieren. Code of Practice voor het Immuniseren van Proefdieren; p. 27-31. Veterinaire Hoofdinspectie, Maart 1993

Akkermans AM, Marsman FM, Hendriksen CFM and Donk vd HJM. Evaluation and validation of a single-dilution potency assay based upon serology of vaccines containing diphtheria toxoid. RIVM Annual Scientific Report 1993. pp.125-128.

Jansen van 't Land C and Hendriksen CFM. Change in locomotor activity pattern: a model for recognition of distress in mice? RIVM Annual Scientific Report 1993. pp.142-145.

Leenaars PPAM, Hendriksen CFM, Angulo AF, Koedam MA and Claassen E. Evaluation in rabbits of several types of adjuvant. Proceedings of the Fifth FELASA symposium, 8-11 June, Brighton UK. pp. 155-161.

Coenraad F.M.Hendriksen, Jacob Woltjes, Arnoud M.Akkermans, Johan W. van der Gun, Frits R.Marsman, Mirjam H.Verschure and Kees Veldman. Interlaboratory validation of *in vitro* serological assay systems to assess the potency of tetanus toxoid in vaccines for veterinary use. *Biologicals* 1994; 22: 257-268.

Ark van de A, Straaten-van de Kapelle van I, Akkermans A, Hendriksen C and Donk van de H. Development of pertussis serological potency test: serological assessment of antibody response induced by whole cell vaccine as an alternative to mouse protection in an intracerebral challenge model. *Biologicals* 1994; 22: 233-242.

Van Loveren H, Gianotten N, Hendriksen CFM, Schuurman HJ, Van der Laan JW. Assessment of immunotoxicity of buprenorphine. *Laboratory Animals* 1994; 28: 355-363.

Hendriksen CFM. Alternatieven voor dierproeven (Alternatives to Animal Testing). *Revue de l'Association Belge des Technologues de Laboratoire.* (1994). 21, 1: 59-69.

Coenraad F.M.Hendriksen, Bernward Garthoff, Henrik Aggerbeck, Lucas Bruckner, Peter Castle, Klaus Cussler, Roland Dobbelaer, Huib van de Donk, Johan van der Gun, Silvie Lefrancois, Julie Milstien, Philip D.Minor, Hubert Mougeot, Bart Rombaut, Hansjorg D.Ronneberger, Jean-Marc Spieser, Ruurd Stolp, Donald W.Straughan, Maria Tollis, Gy Zigtermans. Alternatives to animal testing in the quality control of immunobiologicals: Current status and future prospects. The Report and Recommendations of ECVAM Workshop 4. *ATLA* 1994; 22, 420-434.

Coenraad F.M.Hendriksen. Ersatzmethoden für den Toxinneutralisationstest in der Maus. Ergebnisse eines Europäischen Ringversuchs. *ALTEX (Suppl).* 1994; 11: 30-34.

Leenaars PPAM, Hendriksen CFM, Angulo AF, Koedam MA and Claassen E. Evaluation of several adjuvants as alternative for the use of Freund's adjuvants in rabbits. *Vet.Immunol.Immunopath.* 1994; 40: 225-241.

Hendriksen CFM, Slob W, Gun van der JW, Westendorp JHL, Den Bieman M, Hesp A and Zutphen van LFM. Immunogenicity testing of diphtheria and tetanus vaccines by using isogenic mice with possible implications for potency testing. *Lab. Animals*. 1994; 28: 121-129.

Coenraad F.M.Hendriksen. Replacement, Reduction, and Refinement of Animal Use in Vaccine Production and Testing. *Lab Animal* 1994; 23, 3:24-30.

Balls M, Goldberg AM, Fentem JH, Broadhead CL, Burch RL, Festing MFW, Frazier JM, Hendriksen CFM, Jennings M, van der Kamp MDO, Morton DB, Rowan AN, Russell WMS, Spielmann H, Stephens ML, Stokes WS, Straughan DW, Yager JD, Zurlo J and van Zutphen LFM. ECVAM workshop 'The Three Rs: The Way Forward'. *ATLA* (1995); 23, 838-866

Coenraad Hendriksen and Johan van der Gun. Animal models and alternatives in the quality control of vaccines: are in vitro methods or in vivo methods the scientific equivalent of the emperor's clothes. *ATLA* (1995): 23, 61-73

Hendriksen C.F.M. Development, validation and acceptance of alternative methods in the quality control of vaccines: a case report. *Toxicol. in Vitro* (1995): 9, 6: 815-819

Jansen van't Land C and Hendriksen CFM. Change in locomotor activity pattern in mice: a model for recognition of distress? *Laboratory Animals* (1995), 29: 286-293.

Leenaars PPAM, Hendriksen CFM, Koedam MA, Claassen I and Claassen E. Comparison of adjuvants for immune potentiating properties and side effects in mice. *Veterinary Immunology and Immunopathology* (1995), 48: 123-138.

Hendriksen CFM. Refinement, reduction and replacement in potency testing on batches of Diphtheria, Tetanus and Pertussis vaccine. In: Schoffl H, Spielmann H et al. (eds). *Forschung ohne Tierversuche*. Springer Verlag Wien (1995), 170-178.

Hendriksen CFM. Refinement, Reduction and Replacement in Potency Testing on Batches of Diphtheria, Tetanus and Pertussis vaccine. In: Schoffl H, Spielmann, H. et al. (eds). *Forschung ohne Tierversuche 1995*. Springer-Verlag Wien 1995, 170-178.

Garthoff B, Hendriksen C, Bayol A, Goncalves D, Grauer A, de Leeuw R, van Noordwijk J, Pares M, Pirovano R, Ronneberger H, Spieser J-M, Storing P, Vosbeck K and Weichert H. Safety and efficacy testing of hormones and related products; ECVAM Workshop Report 9, *ATLA* 23, 699-712, 1995

Klaus Cussler und Coenraad F.M. Hendriksen. Stand der Entwicklung von Alternativen bei der Prüfung immunologischer Arzneimittel. In: *Alternativen zu Tierexperimenten*. Gruber F.P. und Spielman (Hrsg) Spektrum Akademischer Verlag Berlin (1996) 163-188

Hendriksen CFM. History of the use of animals in vaccine development and quality control. In: *Replacement, Reduction and Refinement in the Development and Control of Biological Products*. Brown F, Cussler K and Hendriksen C (eds.). *Dev.Biol.Stand.* Vol .86, Karger, Basel (1996), 3-11.

Gun van der J, Akkermans A, Hendriksen C and Donk van de H. Validation of the Toxin-Binding Inhibition (ToBI) test for the estimation of the potency of the Tetanus toxoid component in vaccines. In: *Replacement, Reduction and Refinement in the Development and Control of Biological Products*. Brown F, Cussler K and Hendriksen C (eds). *Dev.Biol.Stand.* Vol.86, Karger, Basel (1996), 199-207.

Ark van der A, Straaten -van de Kapelle van I, Hendriksen C and Donk van de H. Pertussis serological potency test as an alternative to the intracerebral mouse protection test. In: *Replacement, Reduction and Refinement in the Development and Control of Biological Products*. Brown F, Cussler K and Hendriksen C (eds.). *Dev.Biol.Stand.* Vol 86, Karger, Basel (1996), 271-283.

R.Schade, C.Staak, C.Hendriksen, M.Erhard, H.Hugl, G.Koch, A.Larsson, W.Pollmann, M.Regenmortel, E.Rijke, H.Spielmann, H.Steinbusch & D.Straughan. The production of Avian (Egg Yolk) antibodies: IgY. ECVAM workshop Report 21. (1996) ATLA 24: 925-934.

Hendriksen CFM, Rozing J, Kamp van der M and de Leeuw W. The production of monoclonal anti-bodies: are animals still needed? (1996) ATLA 24: 109-110.

PPAM Leenaars, E Claassen & CFM. Hendriksen 1996. Considering the side effects of adjuvants products in immunization procedures. Lab Animal, September 1996, 40-43.

Klaus Cussler & Coenraad Hendriksen. Three Rs approaches in the production and control of vaccines. (abstract). In: Second World Congress on Alternatives in the Life Sciences, 20-24 October 1996, Utrecht, The Netherlands. ATLA, (1996), 24: 135.

Coenraad Hendriksen & Eric Claassen. polyclonal and monoclonal antibodies: guidelines for their production. In: Second World Congress on Alternatives in the Life Sciences, 20-24 October 1996, Utrecht, The Netherlands. ATLA, (1996), 24: 181.

Ineke van Straaten-van de Kapelle, Johan W.van der Gun, Frits R.Marsman, Coenraad F.M.Hendriksen and Huib J.M.van de Donk. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine. Biologicals (1997), 25: 41-57

Leenaars PPAM, Hendriksen CFM, Savelkoul HFJ, Van Rooijen N & Claassen E. Increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination *in vivo*. Immunology (1997): 337-343.

Leenaars PPAM, Koedam MA, Wester PW, Baumans V, Claassen E & Hendriksen CFM. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab.Animals (1998), 32, 387-406.

Leenaars PPAM, Koedam MA, Hendriksen CFM & Claassen E. Immune responses and side effects of five different oil based adjuvants in mice. Vet.Immunology and Immunopathology (1998), 61: 291-304.

McCullough K and Hendriksen CFM. Alternative methods to animal experimentation. In: Veterinary Vaccinology. P-P.Pastoret, J.Blancou, P.Vannier and C.Verschueren eds. Elsevier. Amsterdam (1997), pp.69-112.

Coenraad Hendriksen, Charlotte Jansen van 't Land & Björn Steen. Humane end-points in animal experiments with particular emphasis on the pertussis vac-cine potency test. Proceedings of the Sixth Symposium of the Federation of European Laboratory Animal Science Associations, 19-21 June 1996, Basel, Switzerland. The Royal Society of Medicine Press Ltd.; 83-88 (1996)

Marlies Leenaars, Lex Nagelkerken, Coenraad Hendriksen and Eric Claassen. A model for testing the efficacy of immunization procedures by early cytokine production in mice. In: Animal Alternatives, Welfare and Ethics. L.F.M.van Zutphen and M.Balls (eds.). Elsevier Science B.V. (1997), pp. 995-1002.

Coenraad F.M.Hendriksen and Eric Claassen. Polyclonal and monoclonal antibodies: synopsis of the workshop. In: Animal Alternatives, Welfare and Ethics. L.F.M.van Zutphen and M.Balls (eds.). Elsevier Science B.V. (1997), pp. 1071-1073.

Coenraad Hendriksen. Vaccine development and production. In: Target 2000, Reducing Animal Experiments by 50%. Proceedings of the Conference held by DG XI. Palais des Congres, Brussels. 14-15 April 1997.

C.F.M.Hendriksen. Recommendations of ECVAM for Clostridial vaccines. Pharmeuropa. October 97, 1, 14-17.

C.F.M.Hendriksen. Approaches for the validation of serological methods as an alternative to the challenge procedures. Pharmeuropa. October 97, 1, 76-83.

Festing MFW, Baumans V, Combes RD, Halder M, Hendriksen CFM, Howard BR, Lovell DP, Moore GJ, Overend P and Wilson MS. Reducing the use of laboratory animals in biomedical research: problems and possible solutions. ECVAM Workshop Report 29. *ATLA* 26, 4, 283-301 (1998).

Hendriksen CFM. A call for a European prohibition of monoclonal antibody production by the ascites procedure in laboratory animals. *ATLA*, 523-540 (1998).

Halder M, Embleton MJ, Fischer R, de Geus B, Hendriksen CFL, de Leeuw WA, Marx U and Balls M. Comment on Appendix C of the National Institutes of Health response to the petition of the American Anti-Vivisection Society to prohibit the use of animals in the production of monoclonal antibodies. *ATLA* 26, 4, 549-555 (1998)

De Geus B & Hendriksen CFM. Introduction. In: *In vivo* and *In vitro* production of monoclonal antibodies: current possibilities and future perspectives. De Geus B & Hendriksen CFM (eds.). 74th Forum in Immunology. In: *Research in Immunology*, No.6, Vol. 149: 529-620 (1998)

Hendriksen CFM & De Leeuw W. Production of monoclonal antibodies by the ascites method in laboratory animals. In: *In vivo* and *In vitro* production of monoclonal antibodies: current possibilities and future perspectives. De Geus B & Hendriksen CFM (eds.). 74th Forum in Immunology. In: *Research in Immunology*, No.6, Vol. 149: 529-620 (1998)

Hendriksen C, Spieser J-M, Akkermans A., Balls M, Bruckner L, Cussler K, Daas A, Descamps J, Dobbelaar R, Fentem J, Halder M, van der Kamp M, Lucken R, Milstien J, Sesardic D, Straughan D and Valedares A. Validation of Alternative Methods for the Potency Testing of Vaccines. ECVAM Workshop Report 31. *ATLA* (1998), 26, 747-761.

Hendriksen CFM, Steen B, Cussler K & Morton DB. (1999) Preface. In: *Humane Endpoints in Animal Experiments for Biomedical Research*. Hendriksen CFM & Morton DB (eds). The Royal Society Medicine Press, London (UK). pp. v – vi.

Cussler K, Morton DB & Hendriksen CFM. Humane endpoints in vaccine research and quality control. (1999). In: *Humane Endpoints in Animal Experiments for Biomedical Research*. Hendriksen CFM & Morton DB (eds). The Royal Society Medicine Press, London (UK). pp. 95-101.

Hendriksen CFM, Steen B, Visser J, Cussler K, Morton D & Streijger F (1999). The evaluation of humane endpoints in pertussis vaccine potency testing. In: *Humane Endpoints in Animal Experiments for Biomedical Research*. Hendriksen CFM & Morton DB (eds). The Royal Society Medicine Press, London (UK). pp. 106-113.

Sesardic D & Hendriksen CFM. (1999). Alternatives to animals in the development and control of biological products for human and veterinary use. *Biologicals* 27: 55-57.

P.P.A.M.Leeenaars, C.F.M.Hendriksen, W.A.de Leeuw, F.Carat, et al.. The production of polyclonal antibodies in laboratory animals. *ATLA*, (1999), 27, 1, 79-103.

Coenraad Hendriksen: Alternatives in monoclonal antibody production. The Johns Hopkins Center for alternatives to Animal Testing, Technical Report No.8 (1999), 38-40.

Hendriksen C. (1999) Validation of test methods in the quality control of biologicals. *Dev. Biol.Stand.* 101: 217-221

Vandenberg J, van der Gun JW & Hendriksen CFM. (1999) Evaluation of toxin neutralisation in test systems for diphtheria antibody assessment. *Dev.Biol.Stand.* 101: 105-111.

Winsnes R, Hendriksen C, Sesardic D, Akkermans A & Daas A. (1999) Serological assays as alternatives to the Ph.Eur. challenge test for batch release of tetanus vaccines for human use. *Dev.Biol.Stand.* 101: 277-288.

Coenraad F.M.Hendriksen and Bjorn Steen (2000). Refinement of vaccine potency testing with the use of humane endpoints. *ILAR Journal* 42,2: 105-113.

Coenraad F.M.Hendriksen (2000). Production of monoclonal antibodies by the ascites method: animal welfare implications. Proceedings of the "Production of Monoclonal antibodies" workshop. *Alternatives Research & Development Foundation*. August 29. Bologna. pp. 6-12.

Vleeming W, Hendriksen CFM, Van de Kuil A, Van den Hout JWE & de Wildt DJ. (2000). Mepyramine but not cimetidine or clobenpropit blocks pertussis toxin-induced histamine sensitization in rats. *British Journal of Pharmacology* 129, 1801-1807.

Winsnes R & Hendriksen C. (2000). Collaborative study for the validation of serological methods for potency testing of tetanus toxoid vaccines for human use. PHARMEUROPA, BIO 2000-1, 83-124.

Hendriksen CFM. (2000). Comparison of methods for potency testing of tetanus toxoid vaccines: development and validation of *in vitro* serological methods for tetanus vaccines for human and for veterinary use. PHARMEUROPA, October 2000, pp. 31-39.

Hendriksen CFM. Replacement, reduction and refinement and biologicals: about facts, fiction and frustrations. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Balls M, Van Zeller A-M & Halder M. (eds.). Elsevier, Amsterdam (2000), pp 51-65.

Cussler K, Morton DB & Hendriksen CFM. Possibilities for the use of humane endpoints in vaccine potency tests. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Balls M, Van Zeller A-M & Halder M. (eds.). Elsevier, Amsterdam (2000), pp 915-927.

Hendriksen CFM & Gupta RK. The development of new vaccines without using animals. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Balls M, Van Zeller A-M & Halder M. (eds.). Elsevier, Amsterdam (2000), pp 1677-1679.

Hendriksen CFM. Vaccine development: past, present and future. In: Fighting Infection in the 21st Century. Andrew PW, Oyston P, Smith GL & Stewart-Tull (eds.). Blackwell Science, Inc. Malden (USA), (2000), pp.61-72.

Hendriksen CFM. Monoclonal antibodies: science and production tourism. In: International Conference of the Council of Europe on Ethical Issues Arising from the Application of Biotechnology. ISBN 92-871-4386-2. Starsbourg (2000), pp. 153-159.

Van der Ark A, Van Straaten-Van de Kapelle I, Olander R-M, Enssle K, Jadhav S, Van de Donk H & Hendriksen C. The pertussis serological potency test collaborative study to evaluate replacement of the mouse protection test. *Biologicals* (2000), **28**: 105-118.

Hendriksen C, van der Gun J, Winsnes R, Urdal T, Rautmann G, Esposito-Farese ME. (2001). Collaborative study for the establishment of a European Pharmacopoeia Biological Reference Preparation for serological potency testing of tetanus vaccines for human use: Clostridium tetani guinea pig antiserum (human). *Pharmeuropa*, Spec Issue Biol. (2001) 1 (1):7-11

Leenaars PP, Kersten GF, de Bruijn ML, Hendriksen CF. (2001). An in vitro approach in quality control of toxoid vaccines. *Vaccine* 19(17-19):2729-33

van Straaten I, Levels L, van der Ark A, Thalen M, Hendriksen C.(2002). Toxicity and immunogenicity of pertussis whole cell vaccine in one animal model. *Dev Biol.* 111:47-55

Hendriksen C & Winsnes R (2002). Serological methods form potencyb testing of tetanus toxoid for human use. *Dev Biol.* 111: 131-141

Metz B, Hendriksen CF, Jiskoot W, Kersten GF. (2002). Reduction of animal use in human vaccine quality control. *Vaccine*. 20 : 2411-30

Van de Weerd HA, Aarsen EL, Mulder A, Kruitwagen CL, Hendriksen CF, Baumans V. (2002). Effects of environmental enrichment for mice: variation in experimental results. *J Appl Anim Welf Sci*. 5(2):87-109

Cussler K, Halder M, Hendriksen C. (2002). Future activities: ECVAM and the quality control of biologicals. *Altern Lab Anim*. 30 Suppl 2:225-6.

Halder M, Balls M, Hendriksen C, Cussler K. (2002). ECVAM's activities on biologicals. *Altern Lab Anim*. 30, Suppl 2:125-

Hendriksen C, Cussler K, Halder M. (2002). ECVAM's role in the implementation of the Three Rs concept in the field of biologicals. *Altern Lab Anim*. 30, Suppl 2:41-6

Hendriksen CF. (2002) Refinement, reduction, and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals. *ILAR J.*; 43 Suppl:S43-8

.....

Johannes S, Hartinger J, Hendriksen CF, Morton DB, Cussler K. (2003). Humane endpoints in the efficacy testing of swine erysipelas vaccines. *ALTEX*. 20(1):11-15

Hendriksen, C.F.M., Cussler, K. & Halder, M. (2003). Has ECVAM played a role in the implementation of the three R's concept in the field of biologicals? *ATLA* 30 (2), 41-49.

Hendriksen, C.F.M. , & Hau, J. (2003). Production of polyclonal and monoclonal antibodies In G.L. Hoosier & J. Hau (Eds.), *Handbook of Laboratory Animal Science*, 2nd Edition (pp. 391-413). London: CRC Press LLC.

Hendriksen, C.F.M. (2003). Introduction of the Three Rs concept: Replacement, Reduction, Refinement. In (Ed.), *Replacement, Reduction and Refinement of the Use of Animals in the Quality Control of Vaccines*. EDQM. Proceedings of a symposium: Strassbourg, 7-8 November (pp. 11-15).

Van Meijeren C.E., Vleeming W, van de Kuil T, Manni J, Kegler D, Hendriksen C.F.M. & de Wildt D.J. (2004) In vivo pertussis toxin treatment reduces contraction of rat resistance arteries but not that of mouse trachea. *Eur.Journal.of Pharmacology* 488: 127 – 135.

Halder M, Balls M, Hendriksen C & Cussler. (2004). ECVAM's activities in promoting the Three Rs in the quality control of biologicals. *ATLA* 32, Suppl. 1: 93 –98.

Van Meijeren CE, Vleeming W, van de Kuil T, Gerards AL, Hendriksen CF, de Wildt DJ. (2004). Pertussis toxin-induced histamine sensitisation: an aspecific phenomenon independent from the nitric oxide system? *Eur.Journal.of Pharmacology* 493: 139 – 150.

Hendriksen C. (2004) Reduction of numbers of animals used in the quality control of Biologicals. *ATLA*, 32, suppl. 2: 53 – 59.

Hendriksen C.F.M. (2004). Animal models in Vaccinology. In: *Handbook of Laboratory Animal Science*, 2nd ed. Vol. III Animal Models. Hau J & van Hoosier G.L.Jr. eds.. CRC Press New York 2005: 1-15pp.

Van Meijeren CE, Vleeming W, Dormans JAMA, van de Kuil T, Opperhuizen A, Hendriksen CF, de Wildt DJ. (2004). Pertussis toxin relaxes small arteries with no vascular lesions or vascular smooth muscle cell injury. *Experimental and Toxicologic Pathology* 56. 139 – 143.

Piersma SJ, van der Gun JW, Hendriksen CFM, Thalen M. (2005). Decreased sensitivity of diphtheria toxin of Vero cells cultured in serum-free medium. *Biologicals*, 33: 117-122.

Hendriksen CFM (2005). Introduction: Laboratory Animals and Immunization Procedures: challenges and opportunities. *ILAR Journal* 46, 3: 227-230.

Leenaars M & Hendriksen CFM (2005). Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. *ILAR Journal* 46, 3: 269-280.

Hau J & Hendriksen CFM. (2005). Refinement of polyclonal antibody production by combining oral immunization of chickens with harvest of antibodies from egg yolk. *ILAR Journal* 46, 3: 294-300.

Boo de J & Hendriksen C. (2005). Reduction strategies in animal research: a review of scientific approaches at the intra-experimental, supra-experimental and extra-experimental levels. *ATLA*, 33, 4: 369-379.

Boo de MJ, Rennie AE, Buchanan-Smith HM & Hendriksen CFM (2005). *Animal Welfare*, 14: 327-332.

Hendriksen Coenraad F.M. (2006). Replacement, Reduction and Refinement in the production and quality control of immunobiologicals. *AATEX*, 11 (3): 155-161.

Coenraad Hendriksen & Jeffrey Bajramovic (2006). Vervangen, Verminderen en Verfijnen. Op zoek naar alternatieven. In: *Dieren in Dienst. Biowetenschappen en Maatschappij*, nr.1: 37 – 49.

Piersma SJ, Leenaars MP, Guzylack-Piriou L, Summerfield A, Hendriksen CF & McCullough KC. (2006) An *in vitro* immune response model to determine tetanus toxoid antigen (vaccine) specific immunogenicity: Selection of sensitive assay criteria. *Vaccine* 24 (16): 3076-3083.

Hendriksen CFM (2006). Towards eliminating the use of animals for regulatory required vaccine quality control. *ALTEX*, 23 (3): 187-190.

Hendriksen Coenraad F.M. (2006). Replacement, Reduction and Refinement in Biomedical Research with particular emphasis to the –omics Technologies. *Asia Pacific Biotech.* 10 (20): 1149-1154.

Hendriksen CFM (2006). Ontwikkelingen op het gebied van dierproeven in het biomedisch onderzoek. *Ned.Tijdsch.Geneesk.* 150 (52): 2857-2862.

Verboost PM, Van der Valk J & Hendriksen CFM (2007). Effects of the introduction on *in vitro* assays on the use of experimental animals in pharmacological research. *ATLA*, 35, 2: 223-229.

Cynthia M Verwer, Leo T.M.van der Ven, Ruud van den Bos R & Coenraad F.M.Hendriksen (2007). Effects of housing condition on experimental outcome in a reproduction toxicity study. *Regulatory Toxicology and Pharmacology* 48: 184-193.

Metz B, Brunel F, Chamberlin C, van der Gun J, Halder M, Jiskoot W, Kersten G, van Opstal O, Petersen J.W., Ravetkar S.D., Redhead K, Schwanig M, Wilhelmsen E.S., Vann W.F. and Hendriksen C.F.M. The Potential of Physicochemical and Immunochemical Assays to Replace Animal Tests in the Quality Control of Toxoid Vaccines. *ATLA* 35, 323-331, 2007

Schiffelers MJ, Blaauboer BJ, Fentener van Vlissingen JM, Kuil J, Remie R, Thuring JW, Vaal MA, Hendriksen CF. (2007). Factors stimulating or obstructing the implementation of the 3Rs in the regulatory process. *ALTEX* 24(4): 271-278.

Mahabir A.G., van Benthem J, Kostern H, Lynch A.M., Bailey L, de Vries A, Hendriksen C.F.M. and van Steeg H, (2008) Detecting genotoxic effects of potential clastogens: an *in vivo* study using the LacZ plasmid and the MuTMMouse model. *Mutation Research – Mutat.Research* 652 (2): 151-157..

Hendriksen C.F.M., Arciniega J.L., Bruckner L, Chevalier M, Coppens E, Descamps J, Duchene M, Dusek D.M., Halder M, Kreeftenberg H, Maes A, Redhead K, Ravetkar S.D., Spieser J-M, Swam H. (2008) The consistency approach for the quality control of vaccines. *Biologicals* 36 (1): 73-77.

Bottini AA, Alepee N, Phillips B, Gribaldo L, De Silva O, Hartung T, Hendriksen C, Kuil J, Pazos P, Rhein C, Schiffelers MJ, Stokes W, Theobald A, Vidal JM, Van de Sandt H, Breier S, Sintes JR, Blaauboer B. (2008) Optimisation of the post-validation process: the report and recommendations of ECVAM Workshop 67. *ATLA* 36(3): 353-366

Anuska G. Mahabir, Mirjam Schaap, Peter Theunissen, Jan van Benthem, Jeroen Essers, Annemieke de Vries, Coenraad F.M. Hendriksen, Harry van Steeg (2008). DNA-repair-deficient *Rad54/Rad54B* mice are more sensitive to clastogens than wild-type mice. *Toxicology Letters* 183: 112-117.

Von Hunolstein C, Gomez Miguel MJ, Pezzella C, Scopetti F, Behr-Gross ME, Halder M, Hoffmann S, Levels L, van der Gun J, Hendriksen C. (2008). Evaluation of two serological methods for potency testing of whole cell pertussis vaccines. *Pharmeuropa Bio.* 1: 7-18.

Verwer CM, van Amerongen G, van den Bos R & Hendriksen CFM. (2009). Handling effects of body weight and behaviour of grouped-housed male rabbits in a laboratory setting. *Applied Animal Behaviour Science* 117: 93-102.

Mahabir AG, Zwart E, Schaap M, van Benthem J, de Vries A, Hernandez LG, Hendriksen FM, Harry van Steeg (2009). LaZ Mouse embryonic fibroblast detect both clastogens and mutagens. *Mutat.Res.* 666 (1-2): 50-56.

Hendriksen CF. (2009). Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. *Expert Rev.Vaccines* 8(3): 313-322.

Verwer CM, van der Ark A, van Amerongen G, van den Bos R & Hendriksen CF. (2009). Reducing variation in a rabbit vaccine safety study with particular emphasis on housing conditions and handling. *Lab.Animal.* 43(2): 155-164.

Ohl F, Koëter HBWM, Hendriksen CFM. (2009). Looking into the crystal ball. Verslag van het symposium. *Biotechniek* 48, 2: 47-51. .

Anuska G. Mahabir Mirjam M. Schaap, Jeroen L.A. Pennings, Jan van Benthem, Coenraad F.M. Hendriksen, Harry van Steeg. (2010) Comparison of clastogen-induced gene expression profiles in wild-type and DNA repair-deficient *Rad54/Rad54B* cells. *BMC Genomics* 11-24.

Marieke E. Hoonakker, Nicole Ruitkamp & Coenraad F.M. Hendriksen. (2010) The cAMP assay: a functional in vitro alternative to the in vivo Histamine Sensitization test. *Vaccine*, 28(5): 1347-1352.

De Mattia F, Chapsal JM, Descamp J, Halder M, Jarrett N, Kross I, Mortiaux F, Ponsar C, Redhead K, McCelvie J and Hendriksen C. 2011. The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs. *Biologicals* 39(1): 59 – 65.

Midtlyng PJ, Hendriksen C, Balks E, Bruckner L, Elsen L, Evensen O, Fyrand K, Guy A, Halder M, Hawkins P, Kisen G, Romstad AB, Saloni K, Smith P, Sneddon LU. (2011) Three Rs Approaches in the Production and Quality Control of Fish Vaccines. *Biologicals* 39(2):117-28. Epub 2011 Mar 2.

Jennings M, Morton DB, Charton E, Cooper J, Hendriksen C, Martin S, Pearce MC, Price S, Redhead K, Reed N, Simmons H, Spencer S, Willingale H. Application of the Three Rs to challenge assays used in vaccine testing: tenth report of the BVA/AVMA/FRAME/RSPCA/UFPAW Joint Working Group on Refinement. *Biologicals*. 2010 Nov;38(6):684-95. Epub 2010 Aug 17.